Endothelial stimulation by small lymphocytic lymphoma correlates with secreted levels of basic fibroblastic growth factor
Lisa Rimsza
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorKaren Pastos
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorKenneth Massey
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorRaul Braylan
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorLisa Rimsza
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorKaren Pastos
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorKenneth Massey
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorRaul Braylan
Department of Pathology, Immunology and Laboratory Medicine, Division of Hematopathology, University of Florida, Gainesville, FL, USA
Search for more papers by this authorAbstract
Summary. Lymph nodes (LN) involved with small lympho- cytic lymphoma (SLL) reportedly contain increased numbers of microvessels that may constitute a therapeutic target in this disease. We investigated the secretion of the angiogenic growth factor, basic fibroblastic growth factor (bFGF), from primary tissue cultures of 15 LN with SLL and 10 reactive LN. bFGF was detected from the resulting conditioned media (CM) in 13/15 SLL samples (mean 92 ± 30, range 5–420 pg/ml) but was undetectable in CM from all reactive lymph nodes. CM was also used in a 72-h human umbilical vein endothelial cell (HUVEC) proliferation assay. HUVEC proliferation increased in the presence of SLL CM (70 ± 17%, range −4–194%), proportional to secreted levels of bFGF (R2 = 0·95), and was reversed by depleting bFGF from CM. Previous SLL studies have examined either patient serum samples or paraffin-embedded lymph node tissue sections. This is the first study to examine the secretion of an angiogenic growth factor from primary cultures of lymph node cells. Our results indicate that bFGF is probably the primary mediator responsible for increased angiogenesis in involved nodes. These findings may be pertinent to future investigation into the mechanisms of increased angiogenesis in SLL.
References
- Aguayo, A., Kantarjian, H., Talpaz, M., Estey, E., Koller, C., Estrov, Z., Allred, E., Keating, M. & Barlogie, B.A.M. (1998) Increased angiogenesis in chronic myeloid leukemia and myelodysplastic syndromes. Blood, 92, 607a.
- Aguayo, A., O'Brien, S., Keating, M., Manshouri, T., Gidel, C., Barlogie, B., Beran, M., Koller, C., Kantarjian, H. & Albitar, M. (2000) Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood, 96, 768–770.
- Bairey, O., Zimra, Y., Shaklai, M. & Rabizadeh, E. (2001) Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 113, 400–406.
- Barillari, G., Sgadari, C., Fiorelli, V., Samaniego, F., Colombini, S., Manzari, V., Modesti, A., Nair, B.C., Cafaro, A., Sturzl, M. & Ensoli, B. (1999) The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood, 94, 663–672.
- Bellamy, W.T., Richter, L., Frutiger, Y. & Grogan, T.M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59, 728–733.
- Bertolini, F., Paolucci, M., Peccatori, F., Cinieri, S., Agazzi, A., Ferrucci, P.F., Cocorocchio, E., Goldhirsch, A. & Martinelli, G. (1999) Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. British Journal of Haematology, 106, 504–509.
- Bertolini, F., Fusetti, L., Mancuso, P., Gobbi, A., Corsini, C., Ferrucci, P.F., Martinelli, G. & Pruneri, G. (2000) Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood, 96, 282–287.
- Brown, K.J., Maynes, S.F., Bezos, A., Maguire, D.J., Ford, M.D. & Parish, C.R. (1996) A novel in vitro assay for human angiogenesis. Laboratory Investigation, 75, 539–555.
- Chen, C.H., Jiang, W., Via, D.P., Luo, S., Li, T.R., Lee, Y.T. & Henry, P.D. (2000) Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation, 101, 171–177.
- Chen, H., Treweeke, A.T., West, D.C., Till, K.J., Cawley, J.C., Zuzel, M. & Toh, C.H. (2000) In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood, 96, 3181–3187.
- Duensing, S. & Atzpodien, J. (1995) Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood, 85, 1978–1980.
-
Foss, H.D.,
Araujo, I.,
Demel, G.,
Klotzbach, H.,
Hummel, M. &
Stein, H. (1997) Expression of vascular endothelial growth factor in lymphomas and Castleman's disease.
Journal of Pathology, 183, 44–50.
10.1002/(SICI)1096-9896(199709)183:1<44::AID-PATH1103>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- Fujiwara, Y. & Kaji, T. (1999) Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis. Toxicology, 133, 147–157.
- Hannan, R.L., Kourembanas, S., Flanders, K.C., Rogelj, S.J., Roberts, A.B., Faller, D.V. & Klagsbrun, M. (1988) Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. Growth Factors, 1, 7–17.
- Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S. & Ferrara, N. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841–844.
- Kini, A.R., Kay, N.E. & Peterson, L.C. (2000) Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia, 14, 1414–1418.
- Konig, A., Menzel, T., Lynen, S., Wrazel, L., Rosen, A., Al Katib, A., Raveche, E. & Gabrilove, J.L. (1997) Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia, 11, 258–265.
- Krejci, P., Dvorakova, D., Krahulcova, E., Pachernik, J., Mayer, J., Hampl, A. & Dvorak, P. (2001) FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia, 15, 228–237.
- Menzel, T., Rahman, Z., Calleja, E., White, K., Wilson, E.L., Wieder, R. & Gabrilove, J. (1996) Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood, 87, 1056–1063.
- Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55–63.
- Partridge, C.R., Hawker, Jr,J.R. & Forough, R. (2000) Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration. Journal of Cellular Biochemistry, 78, 487–499.
- Ribatti, D., Vacca, A., Bertossi, M., De Benedictis, G., Roncali, L. & Dammacco, F. (1990) Angiogenesis induced by B-cell non-Hodgkin's lymphomas. Lack of correlation with tumor malignancy and immunologic phenotype. Anticancer Research, 10, 401–406.
- Ribatti, D., Vacca, A., Nico, B., Fanelli, M., Roncali, L. & Dammacco, F. (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. European Journal of Haematology, 56, 45–53.
- Salven, P., Orpana, A., Teerenhovi, L. & Joensuu, H. (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood, 96, 3712–3718.
- Toschi, E., Barillari, G., Sgadari, C., Bacigalupo, I., Cereseto, A., Carlei, D., Palladino, C., Zietz, C., Leone, P., Sturzl, M., Butto, S., Cafaro, A., Monini, P. & Ensoli, B. (2001) Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor. Molecular Biology of the Cell, 12, 2934–2946.
- Vacca, A., Ribatti, D., Roncali, L. & Dammacco, F. (1995) Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. Leukemia and Lymphoma, 20, 27–38.
- Vacca, A., Ribatti, D., Iurlaro, M., Albini, A., Minischetti, M., Bussolino, F., Pellegrino, A., Ria, R., Rusnati, M., Presta, M., Vincenti, V., Persico, M.G. & Dammacco, F. (1998) Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. International Journal of Clinical and Laboratory Research, 28, 55–68.
- Vacca, A., Ribatti, D., Ruco, L., Giacchetta, F., Nico, B., Quondamatteo, F., Ria, R., Iurlaro, M. & Dammacco, F. (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. British Journal of Cancer, 79, 965–970.
- Yao, L., Pike, S.E., Setsuda, J., Parekh, J., Gupta, G., Raffeld, M., Jaffe, E.S. & Tosato, G. (2000) Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood, 96, 1900–1905.